Chronic pelvic pain syndrome (CPPS) and semen quality of Korean men in their 4th decade - Abstract

CP/CPPS is known to be common condition adversely affecting men across a wide range of age.

A number of pharmacologic and nonpharmacologic therapies for CP/CPPS have been investigated by numerous researchers. Our study aimed to evaluate the prevalence of chronic pelvic pain syndrome (CPPS) in Korean men in their thirties and to investigate the effect of CPPS and medical treatment on semen quality. Among 314 men with prostatitis, seventy-four patients with CPPS Class IIIA (23.6%) were eligible and underwent combined therapy with an alpha-blocker in combination with a cyclooxygenase-2 (COX-2) inhibitor. The cases of these seventy-four men were prospectively studied at a medical center in Seoul, Korea. Various characteristics, such as ejaculations per month, semen variables, and the levels of hormones such as follicle-stimulating hormone (FSH), estradiol (E2), luteinizing hormone (LH), testosterone (T) and prolactin (PRL), were evaluated. The mean number of ejaculations per month, the mean daily number of hours spent sitting at work, smoking, body mass index (BMI), the LH and E2 levels and semen parameters (all, p< 0.0001) showed significant differences between the study subjects and the controls. The combined regimen was effective in improving semen quality (all except morphology, p values< 0.05). CPPS Class IIIA, with a notable prevalence among Korean men in their 4th decade, affects semen quality and poses a challenge to fertility. Hence, our results argue in favor of the importance of prostate functionality in determining the quality of semen. Proper treatment of CPPS Class IIIA resulted in improved semen quality. Men, therefore, require proper evaluation of CPPS and treatment by andrologists/urologists prior to planning a natural conception.

Written by:
Byun JS, Yoon TK, Rhee HW, Kim JH, Shin JS, Kim HS, Bak CW.   Are you the author?

Reference: J Androl. 2011 Dec 29. Epub ahead of print.
doi: 10.2164/jandrol.111.014555

PubMed Abstract
PMID: 22207703 Prostatitis Section